Lupin launches authorised generic version of Alinia®
Lupin launches authorised generic version of Alinia®
10 March 2021 | News
Source credit: Shutterstock
Lupin Limited has announced the launch of the authorised, generic version of Alinia® (nitazoxanide) Tablets, 500 mg of Romark Laboratories, LC. Nitazoxanide Tablets, 500 mg, are indicated in the treatment of diarrhoea caused by Giardia lamblia or Cryptosporidium parvum in patients 12 years of age and older.
Nitazoxanide Tablets, 500 mg (RLD: Alinia®) had estimated annual sales of $56 million in the US (IQVIA MAT January 2021).
Lupin Pharma, a subsidiary of the drug major, announced a partnership with Endoceutics, a women s health focused innovative Canadian biotech company, to commercialize Intrarosa in Canada.
Intrarosa is Endoceutic s flagship product indicated for the treatment of postmenopausal vulvovaginal atrophy offered as a vaginal ovule containing 6.5 mg of Prasterone.
Intrarosa was developed in Quebec City, Canada by Endoceutics and will be manufactured in their facilities in Mont Saint Hilaire, Canada. Intrarosa is indicated for postmenopausal vulvovaginal atrophy, it is a vaginal ovule containing 6.5 mg of Prasterone. It comes in blister packs of 28 ovules, with 7 reusable applicators. The recommended dose is one vaginal ovule inserted once a day at bedtime, using the provided applicator or fingers. It is estimated that over 50% of postmenopausal women suffer from the symptoms of vulvovaginal atrophy and that less than 10% of these women are treated with prescription medicines.
Lupin ropes in JIFFY.ai to expand automation initiatives
Lupin ropes in JIFFY.ai to expand automation initiatives
03 March 2021 | News JIFFY.ai will help digitise Lupin data and processes by seamlessly integrating built-in machine learning (ML), robotic process automation (RPA) and intelligent document processing
Source credit: Shutterstock
Global pharma major Lupin Limited and Silicon Valley-based enterprise automation start-up JIFFY.ai have announced a formalised partnership where JIFFY.ai will help to strategically expand Lupin s automation initiatives. This agreement will provide Lupin with the ability to evolve their internal operations via JIFFY.ai s AUTOMATE platform, which provides cloud-native, low-code integrated solutions.
Lupin Launches Penicillamine Tablets USP
Posted On: 2021-03-02 03:15:44 (Time Zone: Arizona, USA)
Global pharma major Lupin Limited (Lupin) today announced the launch of Penicillamine Tablets USP, 250 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.
Penicillamine Tablets USP, 250 mg, are the generic equivalent of Depen® Tablets, 250 mg, of Mylan Specialty, L.P., and indicated in the treatment of Wilson s disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.
Penicillamine Tablets USP, 250 mg (RLD: Depen®) had estimated annual sales of USD 5 million in the U.S. (IQVIA MAT December 2020).
Focus on quality outcomes to change perception on drugs from India: Pharma chiefs thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.